New atlas of small cell lung cancer reveals rare population of stem-like cells with metastatic properties
Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.
Stay updated with breaking news from Systems Biology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma - Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pre-treated (out to 7L / 8L) MUM patients, where historical 1-year OS Rate has been reported at 37% - Darovasertib monotherapy median Overall Survival in MUM is 13.2 months, where historical median OS has been reported at approximately 7 months - Darovasertib and binimetinib combination reports 2 partial responses (PR), ...